A reference matrix answering two questions not covered in any existing ASEAN guide: what specific licenses, QMS certifications, warehouse infrastructure, and pharmacovigilance setup must your distributor hold in each of the 6 major ASEAN markets, and which countries accept FDA or NMPA test reports without full retest.
Two Questions Every Manufacturer Asks — And No Existing ASEAN Guide Answers
There are dozens of articles about ASEAN medical device registration pathways, CSDT format requirements, and country-specific approval timelines. But when a Chinese or Western manufacturer is ready to enter ASEAN, two specific operational questions consistently come up — and they are almost never addressed in existing guides:
Distributor Qualifications: What specific licenses, QMS certifications, warehouse and cold-chain infrastructure, pharmacovigilance capabilities, and local representative status must my distributor or importer actually hold in each ASEAN market?
Test Report Reuse: Which ASEAN countries accept FDA-accredited lab reports as-is? Which accept NMPA-accredited lab reports? Which require full retest by domestically accredited labs? Which accept with bridging declarations?
This post is a reference matrix that answers both questions across the six major ASEAN markets: Singapore (HSA), Malaysia (MDA), Thailand (Thai FDA), Indonesia (Kemenkes), Vietnam (MOH/DMEC), and the Philippines (FDA). It is designed to be printed and used as a planning tool.
Matrix 1: Distributor / Importer Qualification Requirements by Country
Singapore (Health Sciences Authority — HSA)
| Requirement |
Details |
| Local representative type |
Product Registrant (must be a Singapore-registered company) |
| Required license |
Dealer's Licence (Wholesale Licence or Manufacturer's Licence) issued by HSA for all device classes including Class A |
| QMS certification |
GDPMDS SS620 certification required for importers/wholesalers. Valid certification from accredited bodies |
| Qualified Person |
Must designate a Qualified Person responsible for quality management |
| Warehouse/storage |
Must maintain proper storage and handling facilities compliant with GDPMDS requirements |
| Cold-chain infrastructure |
Required for devices with specific storage conditions; temperature monitoring and records mandatory |
| Pharmacovigilance |
Adverse event reporting to HSA required; vigilance reporting obligations apply to dealers |
| Can foreign manufacturer self-register? |
Yes, if they have a Singapore-registered entity. Otherwise, must appoint a local Product Registrant |
| Key regulation |
Health Products (Medical Devices) Regulations 2010 |
| 2026 updates |
HSA migrating to SHARE platform for submissions; revised cybersecurity guidance (GL-04) applies to connected devices |
Malaysia (Medical Device Authority — MDA)
| Requirement |
Details |
| Local representative type |
Authorized Representative (AR) |
| Required license |
Establishment Licence issued by MDA |
| QMS certification |
GDPMD (Good Distribution Practice for Medical Devices) certificate mandatory |
| Warehouse/storage |
GDPMD-compliant storage facilities required; documented SOPs for storage, distribution, complaint handling, recall, and traceability |
| Cold-chain infrastructure |
Required per GDPMD for applicable devices; temperature monitoring documentation mandatory |
| Pharmacovigilance |
Medical device incident reporting to MDA; complaint handling and investigation; field safety corrective action implementation; product recall capability |
| Can foreign manufacturer self-register? |
Only through a Malaysian-registered entity. Foreign manufacturers must appoint a local AR with valid Establishment Licence and GDPMD certificate |
| Key regulation |
Medical Device Act 2012 (Act 737) |
| 2026 updates |
Import permits required effective 2 January 2026 (ePermit via MeDC@St); MDA Circular 1/2026 tightens procurement oversight; MDSAP membership since September 2025; Class A fee revision (RM 500 application + RM 750 registration); aesthetic devices regulation from June 2026 |
Thailand (Thai FDA — Ministry of Public Health)
| Requirement |
Details |
| Local representative type |
Licensed Importer (Thai-registered company) |
| Required license |
Medical Device Import License (or Manufacturing License for local production) |
| QMS certification |
Not a separate distributor QMS requirement for importers, but the manufacturer's ISO 13485 is expected as part of registration submissions |
| Warehouse/storage |
Storage requirements apply under Thai medical device regulations; specific warehouse standards enforced by Thai FDA |
| Cold-chain infrastructure |
Required for applicable devices; must meet Thai FDA storage guidelines |
| Pharmacovigilance |
Adverse event reporting to Thai FDA required; post-market surveillance obligations |
| Can foreign manufacturer self-register? |
No. Must appoint a Thai-licensed importer. The importer holds the registration |
| Key regulation |
Medical Device Act B.E. 2551 (2008) and amendments |
| 2026 updates |
TFDA auto-approval for Class 1 devices introduced; CSDT fulfillment system for license transfers launched; updated labeling and IFU requirements; fast-track program for NCD prevention devices |
Indonesia (Ministry of Health — Kemenkes)
| Requirement |
Details |
| Local representative type |
Local Authorized Representative (LAR) / Independent License Holder |
| Required license |
IDAK (Izin Distributor Alat Kesehatan) — formerly IPAK; valid for 5 years |
| QMS certification |
CDAKB (Cara Distribusi Alat Kesehatan yang Baik — Indonesia's GDP for medical devices) certification mandatory |
| Warehouse/storage |
Must meet CDAKB standards: documented SOPs for storage, distribution, complaint handling, recall, and traceability; temperature monitoring required |
| Cold-chain infrastructure |
Required per CDAKB for devices needing temperature-controlled storage |
| Pharmacovigilance |
Post-market surveillance through Regalkes system; adverse event reporting to Kemenkes |
| Can foreign manufacturer self-register? |
No. Only legally established Indonesian companies can hold IDAK. Foreign manufacturers must: (a) set up a subsidiary (investment threshold >IDR 10 billion / ~USD 760,000), (b) appoint a local distributor with valid IDAK, or (c) appoint an independent third-party license holder |
| Key regulation |
Government Regulation No. 28 of 2025 (updated from GR 28/2024); Minister of Health Regulation No. 4 of 2014 on GDP for medical devices |
| 2026 updates |
Government Regulation No. 28/2025 enacted July 2025 (expanding Health Omnibus Law); CDAKB now mandatory for new NIE applications; internal audit reporting requirement via audit.cdakb@gmail.com; extended evaluation timelines under Permenkes 11/2025 |
Vietnam (Ministry of Health — DMEC/IMDA)
| Requirement |
Details |
| Local representative type |
Registration Holder (MAH) — can be a Vietnamese subsidiary, local distributor, or independent third-party MAH |
| Required license |
Business registration under appropriate medical device business scope; establishment license for import/distribution |
| QMS certification |
Not a separate distributor GDP certification, but manufacturer ISO 13485 is required as part of the submission dossier |
| Warehouse/storage |
Storage requirements under Vietnamese medical device regulations; quality control obligations for all imported devices |
| Cold-chain infrastructure |
Required for applicable devices under Vietnamese Good Distribution Practice guidelines |
| Pharmacovigilance |
Adverse event reporting and field safety corrective actions to MOH; IMDA enforcement under Circular 44/2025, particularly for Class C and D devices |
| Can foreign manufacturer self-register? |
Only via a Vietnamese subsidiary. Otherwise must appoint a local MAH (importer, distributor, or independent regulatory firm) |
| Key regulation |
Law on Pharmacy No. 105/2016/QH13; Circular 57/2025 (updated classification); Circular 44/2025 (post-market) |
| 2026 updates |
New 6-group classification system effective January 2027 under Circular 57/2025; CSDT format required for most device classes; Class A/B registration can complete in 7 days |
Philippines (Food and Drug Administration — FDA)
| Requirement |
Details |
| Local representative type |
Licensed Importer/Distributor |
| Required license |
LTO (License to Operate) from FDA Philippines; CPR (Certificate of Product Registration) required for Class B/C/D devices |
| QMS certification |
ISO 13485 expected for the manufacturer; no separate distributor GDP certification mandated, but new storage and distribution guidelines are being drafted |
| Warehouse/storage |
Storage requirements under FDA Philippines regulations; BOC (Bureau of Customs) accreditation also required |
| Cold-chain infrastructure |
Required for applicable devices per FDA Philippines storage guidelines |
| Pharmacovigilance |
Adverse event reporting to FDA Philippines; recall guidelines drafted as of April 2025 |
| Can foreign manufacturer self-register? |
No. Must appoint a local authorized importer/distributor with valid LTO |
| Key regulation |
Republic Act No. 9711 (FDA Act of 2009); FDA Circular No. 2021-002 (ASEAN harmonized requirements) |
| 2026 updates |
ASEAN harmonized pathway reducing timelines to ~6 months for devices with ASEAN approvals; draft IVD regulation; draft software regulation; draft grouping guidelines; new medical device storage and distribution guidelines under development |
Matrix 1 Summary: Distributor Qualification Comparison
| Requirement |
Singapore |
Malaysia |
Thailand |
Indonesia |
Vietnam |
Philippines |
| License type |
Dealer's Licence |
Establishment Licence + GDPMD |
Import License |
IDAK + CDAKB |
Business registration + establishment license |
LTO + CPR |
| Distributor GDP/QMS |
GDPMDS SS620 |
GDPMD certificate |
None separate |
CDAKB mandatory |
None separate |
Under development |
| ISO 13485 (manufacturer) |
Expected |
Expected |
Expected |
Expected (imports); CPAKB for local mfg |
Expected |
Expected |
| Cold-chain required |
Yes, per GDPMDS |
Yes, per GDPMD |
Yes, per Thai FDA |
Yes, per CDAKB |
Yes, per MOH |
Yes, per FDA PH |
| PV reporting |
Yes (HSA) |
Yes (MDA) |
Yes (Thai FDA) |
Yes (Kemenkes/Regalkes) |
Yes (MOH/IMDA) |
Yes (FDA PH) |
| Foreign mfr can self-register? |
Yes, with SG entity |
No — need AR |
No — need importer |
No — need IDAK holder |
No — need MAH |
No — need LTO holder |
Matrix 2: Test Report Reuse — FDA and NMPA Lab Reports
This matrix addresses whether test reports from FDA-accredited laboratories (for US-market devices) or NMPA-accredited laboratories (for China-market devices) are accepted by each ASEAN regulator, or whether local retesting is required.
General Principles
Most ASEAN regulators follow the AMDD framework, which accepts test reports from ILAC-MRA signatory laboratories (ISO/IEC 17025 accredited). The key question is whether additional steps — such as bridging declarations, local lab verification, or full retest — are required.
Singapore (HSA)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes |
Accepted as supporting evidence. HSA may accept test data from FDA-recognized labs. HSA's abridged and expedited pathways specifically reference FDA approval as qualifying criteria |
| NMPA-accredited lab reports |
Case-by-case |
HSA evaluates NMPA lab reports on their merits. Labs must be ISO/IEC 17025 accredited and ideally ILAC-MRA signatories |
| IEC 17025 accredited lab reports |
Yes |
Accepted if the lab's accreditation scope covers the relevant test parameters |
| Full retest required? |
No |
HSA does not generally require retesting if test reports come from accredited labs with appropriate scope |
| Bridging declaration needed? |
No |
Not typically required for test reports from recognized accreditation bodies |
Malaysia (MDA)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes |
Accepted through the Verification Route when FDA approval is used as reference market evidence. MDA relies on the reference market's assessment of test data |
| NMPA-accredited lab reports |
Limited |
Malaysia launched a reliance pilot with China NMPA for IVDs (July–September 2025), primarily for Chinese-made IVDs. Broader NMPA test report acceptance outside this pilot requires case-by-case assessment |
| IEC 17025 accredited lab reports |
Yes |
Accepted from ILAC-MRA signatory laboratories |
| Full retest required? |
No for Verification Route |
Standard verification pathway relies on reference market evaluation. Full conformity assessment route may require additional evidence |
| Bridging declaration needed? |
Sometimes |
May be required if test conditions or device variants differ between the reference market submission and the Malaysian submission |
Thailand (Thai FDA)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes, with conditions |
Thai FDA accepts foreign test reports as supporting documentation but may require additional verification depending on device class and risk level |
| NMPA-accredited lab reports |
Case-by-case |
Accepted on a case-by-case basis; more scrutiny for higher-risk devices |
| IEC 17025 accredited lab reports |
Yes |
Accepted from accredited labs with appropriate scope; ILAC-MRA membership preferred |
| Full retest required? |
Rarely for Class B; more likely for Class D |
Lower-risk devices generally accept foreign test reports. Higher-risk devices (especially Class D) may require additional testing or verification |
| Bridging declaration needed? |
Sometimes |
Required when test report parameters do not directly map to Thai FDA requirements |
Indonesia (Kemenkes)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes, as supporting evidence |
Kemenkes accepts foreign test reports (including FDA lab reports) as part of the CSDT dossier. However, Kemenkes may require additional testing for certain device categories, particularly electrical safety and electromagnetic compatibility |
| NMPA-accredited lab reports |
Case-by-case |
Accepted on a case-by-case basis. Labs must be accredited and test parameters must align with Indonesian requirements |
| IEC 17025 accredited lab reports |
Yes |
Accepted from accredited labs with relevant scope |
| Full retest required? |
Sometimes |
For specific categories: electrical safety testing (IEC 60601 series) may require verification or retest at an Indonesian-recognized lab. Sterilization validation typically accepted if from accredited lab |
| Bridging declaration needed? |
Yes, commonly |
Kemenkes frequently requires a bridging declaration when test reports reference standards or conditions that differ from Indonesian requirements |
Vietnam (MOH/DMEC)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes, widely accepted |
Vietnam is one of the most receptive ASEAN markets to FDA test reports. Under Circular 05/2022, devices with FDA approval benefit from an expedited pathway, and FDA test data is generally accepted as supporting evidence |
| NMPA-accredited lab reports |
Yes, with conditions |
Vietnam accepts NMPA test reports, particularly from CMA/CNAS-accredited labs that are ILAC-MRA signatories. More common for Chinese-manufactured devices |
| IEC 17025 accredited lab reports |
Yes |
Accepted from ILAC-MRA signatory laboratories |
| Full retest required? |
No for most devices |
Vietnam generally does not require full retest for devices with FDA or other stringent regulatory authority approvals. Lower-risk classes (A/B) have minimal additional testing requirements |
| Bridging declaration needed? |
Rarely |
Not commonly required for FDA-origin test reports. May be needed for NMPA reports if standards differ |
Philippines (FDA Philippines)
| Test Report Source |
Accepted? |
Conditions |
| FDA-accredited lab reports |
Yes |
FDA Philippines accepts US FDA test reports as supporting documentation, particularly under the ASEAN harmonized pathway for devices with existing approvals in reference markets |
| NMPA-accredited lab reports |
Case-by-case |
Accepted on a case-by-case basis, with more scrutiny for higher-risk device classes |
| IEC 17025 accredited lab reports |
Yes |
Accepted from accredited labs with relevant scope; ILAC-MRA membership preferred |
| Full retest required? |
No for ASEAN pathway |
Under the ASEAN harmonized pathway, test reports from recognized markets are accepted. Standard pathway may require more supporting evidence |
| Bridging declaration needed? |
Sometimes |
May be required when test report parameters differ from Philippine requirements |
Matrix 2 Summary: Test Report Reuse Scorecard
| Test Report Source |
Singapore |
Malaysia |
Thailand |
Indonesia |
Vietnam |
Philippines |
| FDA-accredited labs |
Accepted as-is |
Accepted (Verification Route) |
Accepted with conditions |
Accepted as supporting evidence |
Widely accepted |
Accepted |
| NMPA-accredited labs |
Case-by-case |
Limited (IVD pilot only) |
Case-by-case |
Case-by-case |
Accepted with conditions |
Case-by-case |
| IEC 17025 / ILAC-MRA labs |
Accepted |
Accepted |
Accepted |
Accepted |
Accepted |
Accepted |
| Full retest required? |
No |
No (Verification) |
Rarely for low risk |
Sometimes (electrical safety) |
No for most |
No (ASEAN pathway) |
| Bridging declaration? |
No |
Sometimes |
Sometimes |
Yes, commonly |
Rarely |
Sometimes |
Decision Framework: How to Use These Matrices
If You Hold FDA Approval
- Start with Singapore or Vietnam: Both markets accept FDA test reports most readily. Singapore offers the fastest pathway (4–9 months) and serves as a regulatory gateway to other ASEAN markets through reliance pathways.
- Use Singapore as leverage for Malaysia: The permanent MDA–HSA reliance programme (operational since March 2026) lets Singapore-registered devices use the Verification Route for Malaysia, cutting review time by approximately 30 working days.
- Expect minimal retesting: Only Indonesia may require additional electrical safety or EMC testing beyond your FDA test reports.
- Timeline estimate: Singapore (4–9 months) → Malaysia (+3 months) → Thailand/Philippines (+6–12 months parallel) → Indonesia/Vietnam (+6–18 months)
If You Hold NMPA Approval (China)
- Start with Vietnam: Vietnam is the most receptive ASEAN market for NMPA test reports and Chinese-manufactured devices.
- Leverage the Malaysia NMPA IVD pilot: If your device is an IVD manufactured in China, the Malaysia–China NMPA reliance pilot (with potential expansion beyond the initial July–September 2025 phase) may offer a faster route.
- Expect more documentation work: Most ASEAN markets evaluate NMPA test reports on a case-by-case basis. Ensure all labs are CMA/CNAS-accredited and ILAC-MRA signatories.
- Prepare bridging declarations: Indonesia and Thailand commonly require bridging declarations when NMPA test parameters differ from local requirements.
If You Need to Appoint Distributors Across All Six Markets
- Begin distributor qualification screening in parallel with your first registration (typically Singapore). The distributor appointment process takes time in every market.
- Prioritize GDP/GDPMDS/CDAKB-certified distributors: In Singapore, Malaysia, and Indonesia, the distributor's GDP certification is a hard prerequisite for product registration. Do not waste time evaluating distributors who cannot demonstrate current certification.
- Consider independent license holders: In Indonesia and Vietnam, independent third-party license holders (who hold the registration but do not distribute) can give you flexibility to work with multiple distributors. This avoids the single-distributor lock-in that many manufacturers regret.
- Budget for local compliance costs: Each market has distinct costs for distributor setup — GDP certification, warehouse audits, and license fees. Factor these into your ASEAN entry budget alongside the SFDA/MDA/Kemenkes registration fees.
Key Regulatory References
| Country |
Key Regulations |
| Singapore |
Health Products (Medical Devices) Regulations 2010; HSA GN-21-R6 (Change Notifications); GN-24-R2 (Change of Registrant) |
| Malaysia |
Medical Device Act 2012 (Act 737); MDA/GD/0070 (Verification Route); MDA Circular 1/2026; GDPMD requirements |
| Thailand |
Medical Device Act B.E. 2551 (2008); Thai FDA notification requirements; CSDT submission format |
| Indonesia |
Government Regulation No. 28/2025; Permenkes No. 62/2017; Permenkes No. 11/2025; CDAKB requirements under Minister of Health Regulation No. 4/2014 |
| Vietnam |
Law on Pharmacy No. 105/2016/QH13; Circular 57/2025 (classification); Circular 44/2025 (post-market); Circular 05/2022 (expedited pathway) |
| Philippines |
Republic Act No. 9711 (FDA Act of 2009); FDA Circular No. 2021-002 (ASEAN harmonized requirements) |
